At the 2007 Alzheimer's Association International Conference on the Prevention of Dementia - Neurochem's U.S. Principal Investigator Presents Update on Tramiprosate (ALZHEMED(TM))



    WASHINGTON, DC, June 11 /CNW Telbec/ - Paul S. Aisen, M.D., Professor of
Neurology and Medicine at Georgetown University Medical Center, and principal
investigator in the United States of Neurochem Inc.'s North American Phase III
clinical trial for tramiprosate (ALZHEMED(TM)) will present today an update on
Neurochem's investigational product candidate for the treatment of Alzheimer's
disease (AD). The presentation by Dr. Aisen will take place at the
Intervention and Treatment Session, scheduled from 2:30 - 4:30 P.M. (ET), at
the Alzheimer's Association International Conference on Prevention of Dementia
in Washington, DC. In his presentation entitled, A Phase III Study of the
Efficacy, Safety and Disease Modification Effect of Tramiprosate in
Mild-to-Moderate Alzheimer's Disease, Dr. Aisen will review the Phase III
clinical trial and provide an update.
    Neurochem announced in April 2007 that an adjustment to the initial
statistical model, as set out in the statistical plan, would be necessary to
provide accurate results. The procedure to arrive at a reliable model involves
a detailed analysis of potential confounding factors, and Dr. Aisen will
present on the progress to date. In addition, Dr. Aisen will provide an update
on the progress in the analysis of the Phase III clinical trial primary
endpoint data. Some preliminary descriptive data shows numerical differences
in favor of tramiprosate (ALZHEMED(TM)) on the primary clinical endpoint and
also shows differences between groups on the primary disease modification
endpoint as measured by magnetic resonance imaging (MRI). However, work
regarding the adjustment of the statistical model is ongoing and, therefore
results of the Phase III clinical trial cannot be derived from the preliminary
data nor can statistical significance be assigned at this time. Accordingly,
no predictions or conclusions can yet be made regarding the outcome of the
Phase III study.
    Neurochem continues to expect to announce the top-line results of the
trial during the second quarter of this year, although they may not be
available within this timeframe. The actual timing of the release of these
top-line results depends on completing the adjustments to the initial
statistical model.

    Alzheimer's Association News Briefing

    The Alzheimer's Association has invited Dr. Aisen to present on the
tramiprosate (ALZHEMED(TM)) program for inclusion in a news briefing to be
held today, June 11, 2007, at 12:00 P.M. (ET).

    Continuing Medical Education Symposium

    Neurochem is also supporting a CME symposium on June 11 at 6:30 PM at the
conference. The symposium, entitled Confronting the Burgeoning AD Crisis: New
Frontiers, is sponsored by Professional Postgraduate Services(R). The invited
faculty presenters are Howard M. Fillit, MD, Steven T. DeKosky, MD and Serge
Gauthier, MD, and they will examine the burden of AD and assess the need for
improving diagnosis, with a special focus on shifting the treatment paradigm
from managing symptoms to treating the underlying causes of the disease.

    Neurochem Poster Presentations

    Neurochem is also exhibiting three poster presentations on tramiprosate
(ALZHEMED(TM)) at this conference. All posters are displayed in the Exhibit
Hall of the Marriott Wardman Park Hotel, open on June 10 from 10:30 A.M. to
6:30 P.M. (ET) and on June 11 from 9:30 A.M. to 4:30 P.M. (ET).

    
    - Presentation P-187, entitled Tramiprosate Is Neuroprotective and
      Reduces the Levels of Secreted Amyloid-ss in Organotypic Hippocampal
      Slice Cultures, will be presented by lead author Mounia Azzi.
    - André Galarneau will present GABA-Dependent Pathways in the
      Neuroprotective Effect of Tramiprosate against Amyloid-ss Toxicity
      in presentation P-190.
    - Barry D. Greenberg will present Tramiprosate Decreases Amyloid-ss
      Induced Erk1/2 Activity in Primary Rat Neurons by a GABA-Independent
      Pathway in presentation P-192.

    About Neurochem

    Neurochem Inc. is focused on the development and commercialization of
innovative therapeutics to address critical unmet medical needs. Eprodisate
(KIACTA(TM)) is currently being developed for the treatment of Amyloid A (AA)
amyloidosis, and is under regulatory review for marketing approval by the
United States Food and Drug Administration, European Medicines Agency and
Swissmedic. Tramiprosate (ALZHEMED(TM)), for the treatment of Alzheimer's
disease, has completed a Phase III clinical trial in North America and is
currently in a Phase III clinical trial in Europe, while tramiprosate
(CEREBRIL(TM)), for the prevention of Hemorrhagic Stroke caused by Cerebral
Amyloid Angiopathy, has completed a Phase IIa clinical trial.

    To Contact Neurochem

    For additional information on Neurochem and its drug development programs,
please call the North American toll-free number 1 877 680-4500 or visit our
Web Site at: www.neurochem.com.

    This news release contains forward-looking statements regarding
tramiprosate (ALZHEMED(TM)) as well as regarding continuing and further
development efforts. These statements are based on the current analysis and
expectations of management. Drug development necessarily involves numerous
risks and uncertainties, which could cause actual results to differ materially
from this current analysis and these expectations. Analysis regarding the
results of clinical trials may not provide definitive results regarding
safety, tolerability or therapeutic benefits. Even if all the endpoints sought
in the clinical trials were met (which is not certain), there is no certainty
that regulators would ultimately approve tramiprosate (ALZHEMED(TM)) for sale
to the public. Risks and uncertainties may include: failure to demonstrate the
safety, tolerability and efficacy of our product, that actual results may vary
once the final and quality-controlled verification of data and analyses has
been completed, the expense and uncertainty of obtaining regulatory approval,
including from the FDA, and the possibility of having to conduct additional
clinical trials. Further, even if regulatory approval is obtained, therapeutic
products are generally subject to: stringent on-going governmental regulation,
challenges in gaining market acceptance, and competition. Neurochem does not
undertake any obligation to publicly update its forward-looking statements,
whether as a result of new information, future events, or otherwise. Please
see the Annual Information Form for further risk factors that might affect the
Company and its business.
    




For further information:

For further information: Lise Hébert, PhD, Vice President, Corporate
Communications, (450) 680-4572, lhebert@neurochem.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890